Saturday, July 11, 2026

Drug profile · INN

management

management is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 16
Pipeline programs 43
News articles 0
Drug details — management
Class
Route
Patents
16
Programs
43
Data quality
0.70

Quick answer

management is an FDA-listed pharmaceutical active ingredient.

Key facts

INN management

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. 20210184 Phase 3 · Amgen · Chronic Weight Management
  2. AMG 133, Placebo for Maridebart Cafraglutide Phase 3 · Amgen · Chronic Weight Management
  3. APHP210090 Phase 3 · PARItec · Adult patients admitted to the ICU for management of severe
  4. DEXMEDETOMIDINE , 18F-DPA-714 Phase 3 · PARItec · Patients who survive a COVID ARDS in intensive care must be
  5. Enhanced standard management Phase 3 · United Therapeutics Europe · Pacemaker Complication
  6. Exparel Phase 3 · Pacira Ireland · Postoperative Pain Management
  7. Recovery Management Checkups (RMC) Phase 3 · BRIGHT MINDS BIOSCIENCES · Substance Use Disorders
  8. Tramadol Phase 3 · AVENUE THERAPEUTICS · Pain Management

Related patents

  1. US 12329909

    Airway management systems for pulmonary disorder treatment

    Expires 2045-06-12T00:00:00.000Z

    granted
  2. US 11890415

    Airway management systems for pulmonary disorder treatment

    Expires 2044-02-01T00:00:00.000Z

    granted
  3. US 11666634

    Methods and compositions for management of gastrointestinal disorders

    Expires 2043-06-01T00:00:00.000Z

    granted
  4. US 11450420

    Secure smart dosing system with automated delivery, measurement, and management for pills

    Expires 2042-09-15T00:00:00.000Z

    granted
  5. US 11083850

    Secure smart dosing system with automated delivery, measurement, and management

    Expires 2041-08-05T00:00:00.000Z

    granted
  6. US 10736880

    Therapeutics for preterm labor management

    Expires 2040-08-06T00:00:00.000Z

    granted
  7. US 8715751

    Artemisinins in the clinical and veterinary management of kinetoplastid infections

    Expires 2034-05-01T00:00:00.000Z

    granted
  8. AU 2012249536

    Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases

    Expires 2033-11-02T00:00:00.000Z

    granted
  9. US 8546348

    Upregulation of opioid receptors for management

    Expires 2033-09-26T00:00:00.000Z

    granted
  10. US 8469899

    Management of gastro-intestinal disorders

    Expires 2033-06-20T00:00:00.000Z

    granted
  11. US 8435960

    Devices for improved wound management

    Expires 2033-05-02T00:00:00.000Z

    granted
  12. US 8153690

    Cycloalkyl-hydroxyl compounds and compositions for cholesterol management

    Expires 2032-04-05T00:00:00.000Z

    granted
  13. US 8067466

    Cycloalkyl-hydroxyl compounds and compositions for cholesterol management

    Expires 2031-11-24T00:00:00.000Z

    granted
  14. US 7867171

    Management of gastro-intestinal disorders

    Expires 2031-01-06T00:00:00.000Z

    granted
  15. US 7807651

    Methods and materials for pain management

    Expires 2030-09-30T00:00:00.000Z

    granted
  16. US 7566465

    Artemisinins in the clinical and veterinary management of kinetoplastid infections

    Expires 2029-07-23T00:00:00.000Z

    granted

Frequently asked questions

What is management?

management is an FDA-listed pharmaceutical active ingredient.